© 2019 Genprex Inc. All Rights Reserved.
The passion for gene therapy and the new era of cell and gene-based medicine has made its way to the mainstream for treatment of serious diseases.
Genprex's Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference in New York City on September 4, 2019.
Company’s recent performance sets path for future milestones, commercialization
Genprex's newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.